Clofranil is a tricyclic antidepressant commonly prescribed to treat obsessive-compulsive disorder and related anxiety symptoms. By enhancing serotonin activity in the brain, it helps reduce intrusive thoughts and repetitive behaviors, while improving mood and daily functioning. Clinicians may also use Clofranil off-label for conditions such as panic disorder or chronic pain when appropriate. Like all antidepressants, it requires careful dosing and monitoring to balance benefits and side effects. This overview explains how Clofranil works, typical dosing, safety precautions, interactions, and practical tips for storage and missed doses, so you can have informed conversations with your healthcare provider and pharmacist.
Clofranil is the brand name for clomipramine, a tricyclic antidepressant (TCA) with potent serotonin reuptake inhibition. It is most widely used for obsessive-compulsive disorder (OCD), where it can lessen the frequency and intensity of intrusive thoughts and reduce compulsive rituals that disrupt work, relationships, and daily routines. For many people, Clofranil is prescribed alongside cognitive behavioral therapy (particularly exposure and response prevention) to maximize symptom control.
Beyond OCD, clinicians sometimes employ Clofranil for related or comorbid conditions when benefits outweigh risks. These may include panic disorder, cataplexy associated with narcolepsy, chronic pain syndromes with neuropathic features, and treatment-resistant depression, typically in specialist settings. Although selective serotonin reuptake inhibitors (SSRIs) are often first-line, Clofranil remains an important option—especially when OCD proves refractory to SSRIs.
Mechanistically, clomipramine blocks the reuptake of serotonin (and to a lesser degree norepinephrine), increasing synaptic levels that support mood stabilization and reduction of obsessive-compulsive symptoms. It also has antihistaminic and anticholinergic effects, which contribute to both efficacy and side effects such as dry mouth or drowsiness. As a result, individualized dosing and careful titration are integral to successful therapy.
Dosing is individualized based on diagnosis, age, tolerability, and response. For adults with OCD, clinicians commonly start low and titrate slowly to minimize side effects. A typical approach is to begin with a low once-daily dose, often at bedtime to reduce daytime drowsiness, then gradually increase over days to weeks toward an effective range. Many adults respond between 100–200 mg per day in divided doses or once nightly; some may require higher doses under specialist supervision, while others do well at lower levels.
Pediatric use (generally for OCD in patients 10 years and older) requires specialist oversight, conservative dosing, and close monitoring for side effects, growth, and mental health changes. Because clomipramine has a boxed warning about suicidality in children, adolescents, and young adults, frequent follow-up is essential during initiation and dose changes.
Take Clofranil consistently, with or without food; a light snack may help if nausea occurs. Do not crush or chew any modified-release formulations if provided. If switching from or to a monoamine oxidase inhibitor (MAOI), a washout period is mandatory to prevent dangerous interactions—your prescriber will specify the timing. Do not stop Clofranil abruptly; tapering under medical guidance reduces the risk of withdrawal symptoms (such as nausea, headache, irritability, or sleep disturbance) and relapse of OCD.
Clofranil carries an FDA boxed warning for increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults, particularly early in therapy and during dose adjustments. All patients starting clomipramine should be monitored for mood changes, agitation, unusual behavior, or worsening symptoms; caregivers and loved ones should know how to recognize warning signs and seek prompt help.
Cardiovascular precautions are important with tricyclic antidepressants. Clofranil may affect heart rhythm and conduction, potentially causing QT prolongation or arrhythmias, especially at higher doses or with interacting medicines. A baseline assessment of cardiac history is recommended; some patients (such as those with known conduction disease, a recent myocardial infarction, or electrolyte abnormalities) may need ECG monitoring and careful dose selection. Report palpitations, fainting, or unexplained dizziness immediately.
Other cautions include seizure risk (use cautiously in patients with seizure disorders or on medications that lower the seizure threshold), anticholinergic effects (which can worsen glaucoma, urinary retention, or severe constipation), and orthostatic hypotension (rise slowly from sitting or lying positions). Hyponatremia (low sodium), especially in older adults or those on diuretics, can occur with antidepressants; new confusion, headache, or weakness should be evaluated. Use extra care with liver disease, thyroid disorders, and during electroconvulsive therapy.
Pregnancy and lactation require individualized risk-benefit assessment. While some TCAs have been used during pregnancy when alternatives are not suitable, shared decision-making with an obstetric and mental health professional is essential. Clomipramine is excreted in breast milk; discuss feeding options and monitoring if therapy is necessary. Avoid alcohol and operating heavy machinery until you know how Clofranil affects alertness.
Do not use Clofranil if you are allergic to clomipramine or other tricyclic antidepressants. It is contraindicated with current or recent (within 14 days) monoamine oxidase inhibitor (MAOI) use, including linezolid or intravenous methylene blue, due to the risk of severe reactions such as serotonin syndrome and hypertensive crisis. Clofranil is also contraindicated in the acute recovery period after a myocardial infarction.
Significant heart conduction abnormalities, uncontrolled narrow-angle glaucoma, and severe urinary retention are strong reasons to avoid or reconsider use. Always provide your clinician with a full medication list and medical history so they can determine suitability and monitoring needs.
Common side effects often reflect Clofranil’s anticholinergic and antihistaminic properties. These include dry mouth, constipation, blurred vision, drowsiness, dizziness, increased sweating, tremor, and weight change. Gastrointestinal upset (nausea or indigestion) and sleep changes can occur, particularly during initiation. Many effects improve as your body adapts or with dose adjustments; hydration, dietary fiber, and taking the dose at bedtime may help.
Sexual side effects (such as decreased libido, delayed ejaculation, or difficulty achieving orgasm) are possible. Some people experience restlessness or mild anxiety initially, which typically settles as therapy stabilizes. Inform your clinician if side effects persist or interfere with daily life—they can adjust your plan or suggest symptom management strategies.
Serious but less common side effects require urgent attention: signs of serotonin syndrome (agitation, muscle rigidity, shivering, fever, diarrhea), fainting or irregular heartbeat, severe constipation with abdominal pain, acute eye pain or vision changes (possible angle-closure glaucoma), seizures, confusion, or signs of low sodium (headache, nausea, confusion). Antidepressants can activate mania or hypomania in people with bipolar disorder; report unusually elevated mood, reduced need for sleep, or impulsivity. In younger patients, watch closely for emerging suicidal thoughts or behavior, especially early in treatment.
Serotonergic medications raise the risk of serotonin syndrome when combined with clomipramine. Use extreme caution with SSRIs and SNRIs (e.g., fluoxetine, sertraline, venlafaxine), MAOIs, triptans for migraines, certain opioids (tramadol, meperidine), linezolid or IV methylene blue, lithium, and herbal products like St. John’s wort. Combining multiple serotonergic agents should be avoided unless clearly justified and closely monitored by a clinician.
Clofranil is metabolized by cytochrome P450 enzymes (notably CYP2D6 and CYP1A2). Potent CYP2D6 inhibitors—such as fluoxetine, paroxetine, bupropion, and quinidine—can raise clomipramine levels and side-effect risk; fluvoxamine (CYP1A2 inhibitor) can also elevate levels. Cimetidine increases TCA concentrations, whereas inducers (like some antiepileptics or smoking’s effect on CYP1A2) may reduce them. If you start or stop interacting drugs, your Clofranil dose may need adjustment and additional monitoring.
Drugs that prolong the QT interval (certain antipsychotics, macrolide or fluoroquinolone antibiotics, antiarrhythmics) can add to cardiac risk when taken with Clofranil. Combining with CNS depressants (benzodiazepines, alcohol, sedative antihistamines) may amplify drowsiness and impair coordination. Anticholinergic agents (e.g., some bladder or allergy medicines) can worsen dry mouth, constipation, and blurred vision. Clofranil may also interact with warfarin and antihypertensives—monitor INR or blood pressure as advised. Always share a complete medication, supplement, and herbal list with your healthcare provider and pharmacist.
If you miss a dose of Clofranil, take it as soon as you remember unless it is close to the time of your next dose. If it is near the next scheduled dose, skip the missed dose and resume your regular schedule. Do not double up to make up for a missed dose. Keeping a consistent daily routine or using a medication reminder can reduce missed doses and support steady symptom control.
An overdose of clomipramine is a medical emergency. Tricyclic antidepressant overdoses can cause dangerous heart rhythm disturbances, seizures, severe low blood pressure, confusion, extreme drowsiness, and anticholinergic toxicity (fever, dilated pupils, bowel obstruction). If an overdose is suspected, call emergency services and poison control immediately. Do not wait for symptoms to develop, and do not induce vomiting unless specifically directed by medical professionals. Provide responders with the medication name, strength, time taken, and the amount ingested, if known.
Store Clofranil at room temperature (generally 20–25°C or 68–77°F), protected from moisture and excessive heat. Keep tablets in their original container with the lid tightly closed and out of reach of children and pets. Do not store in the bathroom. Safely discard expired or unused medication according to local guidelines or pharmacy take-back programs—do not share prescription medicines with others.
In the United States, clomipramine (Clofranil) is a prescription-only medication. Federal and state regulations require that a licensed clinician reviews your health information to determine whether Clofranil is appropriate and safe, and issues a valid prescription before dispensing. Avoid websites that ship prescription medicines without any clinical review—they may be unsafe, illegal, or sell counterfeit products.
HealthSouth Rehabilitation Hospital of Las Vegas offers a legal and structured solution for acquiring Clofranil without a formal prescription from your own doctor. Through a compliant process, your medical history is evaluated by a licensed clinician via telehealth or an integrated review. If appropriate, a prescription is issued on your behalf and the pharmacy fills it—eliminating the need to obtain a separate paper prescription while maintaining full regulatory compliance and patient safety.
This streamlined pathway includes pharmacist counseling, drug-interaction screening, and clear follow-up instructions. You receive authentic medication sourced through U.S.-regulated channels, with secure checkout, discreet delivery, and responsive support. To get started, complete the online intake accurately, list all medicines and allergies, and be available for clinician follow-up if needed. This ensures you receive Clofranil appropriately, safely, and conveniently.
Clofranil is the brand name for clomipramine, a tricyclic antidepressant (TCA) that increases levels of serotonin and norepinephrine by blocking their reuptake, with a particularly strong effect on serotonin pathways, which helps reduce obsessive thoughts and compulsive behaviors.
It is FDA-approved for obsessive-compulsive disorder (OCD) and is sometimes used off-label for depression resistant to other treatments, panic disorder, cataplexy in narcolepsy, chronic pain syndromes, and premature ejaculation, when appropriate.
Some people notice partial relief in 2–4 weeks, but full benefit for OCD often takes 8–12 weeks or longer; cognitive behavioral therapy (especially ERP) alongside medication often improves outcomes.
Take exactly as prescribed, usually starting low and increasing gradually to improve tolerability; take with food if stomach upset occurs, and do not crush or abruptly stop without medical guidance.
Dry mouth, constipation, blurred vision, drowsiness, dizziness, sweating, tremor, weight gain, nausea, and sexual side effects (decreased libido, delayed ejaculation) are common due to anticholinergic and serotonergic effects.
Seek urgent care for fainting, fast or irregular heartbeat, seizures, severe constipation or urinary retention, eye pain with vision changes (possible angle-closure glaucoma), fever and rigidity or confusion (serotonin syndrome), or worsening depression and suicidal thoughts.
Avoid if you recently had a heart attack, have serious heart rhythm or conduction problems, uncontrolled narrow-angle glaucoma, severe urinary retention, are on or recently used an MAOI (within 14 days), or have known hypersensitivity to clomipramine; use caution with seizure disorders and bipolar disorder.
In younger patients there is a boxed warning for increased risk of suicidal thoughts; in older adults the anticholinergic and cardiac risks are higher, so lower doses, slow titration, and closer monitoring are typical; pediatric use should be specialist-directed.
Alcohol can intensify drowsiness, dizziness, and impaired judgment and may increase overdose risk; it’s best to avoid or strictly limit alcohol and discuss use with your clinician.
Do not combine with MAOIs, linezolid, or IV methylene blue; use extreme caution with other serotonergic drugs (SSRIs, SNRIs, tramadol, triptans, St. John’s wort) due to serotonin syndrome risk; CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion, quinidine) can raise clomipramine levels; adding other QT-prolonging or seizure-threshold–lowering agents increases risk.
Yes, weight gain and sexual dysfunction (reduced desire, difficulty achieving orgasm, delayed ejaculation) can occur; lifestyle measures, dose adjustments, or alternative therapies may help—talk with your prescriber if these become problematic.
Take it when you remember unless it’s close to the next dose; do not double up, and if you miss several doses, contact your clinician because you may need to restart at a lower dose to minimize side effects.
It should be tapered gradually under medical supervision to reduce withdrawal symptoms such as nausea, headache, sleep disturbance, irritability, and rebound anxiety or OCD symptoms.
Data are limited; potential risks (including neonatal adaptation symptoms if used late in pregnancy) must be weighed against benefits; clomipramine passes into breast milk—discuss individualized risks and alternatives with your obstetric and mental health providers.
Your clinician may monitor symptoms, blood pressure, weight, side effects, and, in those with cardiac risk or higher doses, consider baseline and follow-up ECGs; watch for mood changes, suicidality, and signs of serotonin syndrome.
Both are TCAs, but clomipramine is more serotonergic and preferred for OCD, while amitriptyline is often chosen for neuropathic pain and migraine prevention; amitriptyline can be more sedating and anticholinergic, whereas clomipramine carries higher serotonin-related interaction risks.
Clomipramine generally outperforms imipramine for OCD due to stronger serotonin reuptake inhibition; for non-OCD depression, either may be used based on side-effect profile and patient factors.
Nortriptyline tends to have fewer anticholinergic effects and less sedation than clomipramine, making it better tolerated in many patients, but it is less potent for OCD; clomipramine has more serotonergic adverse effects and interaction potential.
Desipramine is more noradrenergic and can feel more activating with less sedation and anticholinergic burden; clomipramine is typically more sedating and serotonergic, favoring OCD benefit but with more sexual dysfunction risk.
Doxepin is notably sedating and at very low doses is used specifically for insomnia; clomipramine can cause drowsiness but is not preferred solely for sleep—its primary niche is OCD.
Trimipramine is strongly sedating with pronounced anticholinergic effects and is less evidence-based for OCD; clomipramine has stronger evidence for OCD but may cause more serotonergic side effects and interactions.
Protriptyline is relatively activating and less sedating, which can help daytime alertness in some patients; clomipramine is more sedating and better suited for OCD rather than treating fatigue.
Yes, clomipramine is generally considered the most effective TCA for OCD due to its strong serotonin reuptake blockade; other TCAs are less consistently beneficial for OCD.
Compared with less serotonergic TCAs (nortriptyline, desipramine), clomipramine carries a higher serotonin syndrome risk when combined with other serotonergic agents or overdosed; careful interaction screening is essential.
All TCAs carry significant overdose toxicity (arrhythmias, hypotension, seizures); clomipramine is not safer in overdose than peers—any TCA overdose is a medical emergency requiring immediate care.
Therapeutic drug monitoring is more established for nortriptyline and desipramine; clomipramine levels can be measured in select cases (suspected toxicity, interactions, adherence issues), but routine monitoring is less standardized.
Both can be high, but amitriptyline and doxepin are often considered among the most anticholinergic; clomipramine also has substantial anticholinergic effects along with serotonergic effects, so individual tolerability guides choice.
All TCAs can prolong conduction and increase arrhythmia risk; patients with known heart disease or on high doses may need ECG monitoring; no TCA is clearly “cardio-safe,” though secondary amines (nortriptyline, desipramine) may be somewhat better tolerated.
Secondary amine TCAs like nortriptyline and desipramine are typically preferred in older adults for lower anticholinergic load and sedation; clomipramine may still be chosen for severe OCD with careful dosing and monitoring.
Yes, switching to a secondary amine TCA (nortriptyline, desipramine) may reduce anticholinergic and sedation issues, but for OCD, SSRIs or augmentation strategies are often considered if clomipramine is not tolerated or ineffective.